275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2022. Parexel International Corporation.
275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300
2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170
© 2000-2022. Parexel International Corporation.
Flexibility is one of the most powerful tools in your trial design arsenal. That’s why Adaptive Trial Designs give you the opportunity to reduce risk of failure by factoring in analyses at key points so study design parameters like sample size, dosage, or patient selection can be adjusted accordingly.
In fact, a 2018 report we commissioned called The Innovation Imperative: The Future of Drug Development by The Economist Intelligence Unit (EIU) found that adaptive trial designs boost a new therapy’s likelihood of launch by 13% on average. That percentage climbs even higher in certain therapeutic areas – up to 32% for oncology. However, although this approach is encouraging, it’s still not widely used.
By implementing Adaptive Trial Designs you have the opportunity to carefully evaluate clinical data in real-time, so you can make informed decisions to change the direction of the study for a better chance of success. A well-designed and executed Adaptive Trial Design can:
Types of Adaptations | Description |
---|---|
Adaptive dose finding | Used to identify the minimum effective dose (MED) and/or the maximum tolerable dose (MTD). Continuous reassessment method (CRM) or a Bayesian Logistic Regression Model (BLRM) |
Population enrichment (e.g., based on biomarker or pharmacogenomic data) | Unblinded interim analysis for subsets of interest for identifying sub-populations with significantly higher response to treatment based on scientific rationales. Subjects may undergo biomarker or genomic testing to determine eligibility for participation in the clinical trail or to enable interim decisions to continue with selected sub-populations or the full population |
Sample size re-estimation (SSR) | Sample size adjustments or re-estimation based on unblinded interim data while not inflating the false-positive probability at the final analysis |
Adaptive randomization | Modification of randomization scheduled based on accumulating study data like baseline covariates or responses |
Seamless Phase I/II studies - dose escalation and dose expansion trials | Combines dose escalation with an expansion phase to generate first activity data |
Seamless Phase II/III | Combines a Phase II and Phase III into one trial, incorporates a decision to adapt the study at an interim analysis and uses data before and after the adaptation in the final analysis |
Master protocols | Includes umbrella, basket and platform designs. Master protocols can be very beneficial in the early development to screen different compounds in the portfolio and select the best for each of the indications or test one compound in several indications to select those indications where a compound is particularly effective. Umbrella designs investigate multiple treatments for a single disease whereas basket trials evaluate a single drug in multiple diseases or disease subtypes (e.g., different tumor types that share the genomic characteristics). Platform trials evaluate multiple treatments in multiple diseases and permit treatment regimens to be added or removed based on pre-specified decision algorithms |
Inclusion of real-world data (RWD) | Real-world data as part of development, forming synthetic control arms |
More services we provide:
Learn how to evaluate interim data at pre-defined points and then adapt your study design parameters to optimize outcomes.
Visit our Preference Center to provide, view and edit your communication preferences, topics of interest, and contact information.
Practically Speaking: Driving Clinical Transformation, Part One
Watch now
Preparing for a Risk-based Future
View now
Crafting a genomics strategy early is key for successful oncology drug development
View now
mHealth Innovation_Identifying the Best Patient-Centered Tech for Clinical Trials
View now
A multi-pronged and customized approach to rare disease clinical trial patient identification and recruitment
View now
Browse the Parexel Resource Center for our latest content on clinical trial supplies, logistics, innovation, drug safety, cell & gene therapy, and more!
Practically Speaking: Driving Clinical Transformation, Part One
Watch Now
Preparing for a Risk-based Future
View Now
Crafting a genomics strategy early is key for successful oncology drug development
View Now
mHealth Innovation_Identifying the Best Patient-Centered Tech for Clinical Trials
View Now
A multi-pronged and customized approach to rare disease clinical trial patient identification and recruitment
View Now
Putting AI to Work in Your Safety Program
View Now
Master Protocols from Design to Delivery
View Now
Successful Wearable Device Selection within the Clinical Trials Industry
View Now
Real-world evidence in APAC
View Now
PharmaVOICE RWE Showcase -The RWE Evolution
View Now
Patient Sensors Solution Factsheet
View Now
Modifying Methods as seen in International Clinical Trials
View Now
We are always available for a conversation.